Diabetes Mellitus, Type 2, Hyperglycemia
Conditions
Brief summary
Many hospitals have begun giving insulin to nearly all patients with diabetes while they are in the hospital even if a patient does not use insulin at home. Controlling blood sugar with insulin when a patient is hospitalized is believed to reduce the risk of complications and death, but research has not demonstrated these benefits except in patients who are critically ill. The purpose of this study, therefore, is to evaluate whether such insulin therapy actually does reduce in-hospital complications, deaths, need for intensive care, or length of stay in the hospital.
Detailed description
The primary aim of the proposed study is to determine if physiologic insulin therapy administered to general hospital inpatients with hyperglycemia favorably affects in-hospital complications and mortality, need for intensive care, or length of stay. The secondary aim is to determine if the magnitude of benefit derived from this therapy differs (a) in patients with known vs. newly diagnosed diabetes, or (b) in medical vs. surgical patients. The study will analyze data from a natural experiment that occurred when the applicant institution introduced universal physiologic insulin therapy as the standard of care for hyperglycemia. A quasi-experimental before-and-after study will compare in-hospital complications, mortality, and resource use in patients with comorbid type 2 diabetes before vs. after implementation of this standard (n≈6400). Outcomes measured at 7 nearby acute-care teaching hospitals during the same two time intervals will provide parallel control data (n≈35,000). Data from the control hospitals will make it possible to evaluate whether temporal changes in patient characteristics or other variables affecting hospitals in the region could explain effects that might otherwise be erroneously attributed to the intervention. Given the high prevalence of comorbid diabetes in the hospital and the possibility that universal physiologic insulin for managing hyperglycemia may not deliver the intended benefit or could even do more harm than good, answering this question is an important goal.
Interventions
OTHERPhysiologic Insulin Therapy
OTHERSliding-Scale Insulin Therapy
Sponsors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Winthrop University Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes
Exclusion criteria
* Pregnant * Admitted directly to an intensive care unit * Length of stay \<2 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transfer to intensive care unit (y/n) | Upon hospital discharge (median length of stay, 5 days) | Assigned y if patient is transferred to an intensive care unit for any length of time; otherwise, assigned n. |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of inpatient days involving any hypoglycemia (blood glucose<70 mg/dL) | Upon hospital discharge (median length of stay, 5 days) |
| Proportion of inpatient days involving severe hypoglycemia (blood glucose<40 mg/dL) | Upon hospital discharge (median length of stay, 5 days) |
| Proportion of inpatient days involving any hyperglycemia (blood glucose>200 mg/dL) | Upon hospital discharge (median length of stay, 5 days) |
| Day-weighted proportion of blood glucose values within target range (100-180 mg/dL) | Upon hospital discharge (median length of stay, 5 days) |
| Development of any complication (y/n) | Upon hospital discharge (median length of stay, 5 days) |
| In-hospital death (y/n) | Upon hospital discharge (median length of stay, 5 days) |
| Proportion of inpatient days involving severe hyperglycemia (blood glucose>300 mg/dL) | Upon hospital discharge (median length of stay, 5 days) |
Countries
United States
Outcome results
None listed